NEW YORK – Euroimmun will sell Oncgnostics'cervical cancer test in parts of Europe under an agreement announced on Thursday.
Euroimmun, a PerkinElmer subsidiary, will sell the GynTect test in Portugal, Italy, Turkey, and Poland. Financial and other terms of the deal were not disclosed.
Germany-based Oncgnostics added that it expects the test to be approved by regulators in Canada and to be sold there by the end of the year.
The PCR-based test detects DNA methylation and is performed in Oncgnostics laboratory with results available in a few days, according to the firm's website.
Euroimmun offers its own EuroArray HPV, a molecular test for detecting and genotyping human papillomavirus, and with the addition of GynTect, it "now has a complete package for cervical cancer diagnosis," Euroimmun CEO Wolfgang Schlumberger said in a statement.